Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study

• Published in: Journal of gynecologic oncology Vol. 24; no. 4; pp. 359 - 366
• Main Authors: Prunella Blinman, Corona Gainford, Mark Donoghoe, Julie Martyn, Penny Blomfield, Peter Grant, Ganessan Kichenadasse, Michelle Vaughan, Alison Brand, Catherine Shannon, Val Gebski, Martin Stockler
• Format: Journal Article
• Language: Korean
• Published: 대한부인종양학회 30.10.2013
• Subjects: Chemotherapy; Decision-making; Ovarian neoplasms; Peritoneal infusions; Quality of life
• ISSN: 2005-0380

Objective: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about its toxicity, inconvenience and acceptability to patients. The purposes of this study were to determine the regimen’s feasibility, adverse events, catheter-related complications, progression-free survival, health-related quality of life (HRQL), and patients’ preferences for IP versus intravenous (IV) chemotherapy. Methods: We conducted a single arm, multi-center study of IP chemotherapy with IV paclitaxel 135 mg/m2 (D1) over 3 hours, IP cisplatin 75 mg/m2 (D2), and IP paclitaxel 60 mg/m2 (D8) for 6 cycles in women with optimally debulked stage III ovarian or related cancers. Results: Thirty-eight eligible patients were recruited from 12 sites between July 2007 and December 2009. Seventy-one percent (n=27) completed at least 4 cycles and 63% (n=24) completed all 6 cycles. Grade 3 or 4 adverse events included nausea (n=2), vomiting (n=2), abdominal pain (n=2), and diarrhea (n=1), but not febrile neutropenia, neurotoxicity, or nephropathy. There were no treatment-related deaths. Catheter-related complications were the most frequent cause of early discontinuation of treatment (16 patients, 21%). Apart from neurotoxicity HRQL which worsened over time, HRQL was stable or improved with time. Most patients (≥50%) judged moderate benefits (e.g., an extra 6 months survival time or a 5% improvement in survival rates) necessary to make IP chemotherapy worthwhile. Conclusion: IP chemotherapy was feasible, tolerable, and most participants considered moderate survival benefits sufficient to warrant the adverse effects and inconvenience.